外科理论与实践

外科理论与实践 >

2020 , Vol. 25 >Issue 01: 10 - 14

DOI: https://doi.org/10.16139/j.1007-9610.2020.01.003

专家论坛

肝动脉灌注化疗的现状与前景

展开
  • 中山大学肿瘤防治中心 肝脏外科 华南肿瘤学国家重点实验室 肿瘤医学协同创新中心,广东 广州 510060

收稿日期: 2019-10-09

  网络出版日期: 2020-02-25

基金资助

国家重点研发计划重点专项(2017YFA0505803);国家杰出青年科学基金(81625017);国家自然科学基金(815 72385);国家科技重大专项(2018ZX10302-205);2017年度广东省特殊支持人才计划广东省科技创新领军人才

收起

Current status and future perspective of hepatic artery infusion chemotherapy

Expand

Received date: 2019-10-09

  Online published: 2020-02-25

Fold

本文引用格式

石明, 何敏柯, 陈敏山 . 肝动脉灌注化疗的现状与前景[J]. 外科理论与实践, 2020 , 25(01) : 10 -14 . DOI: 10.16139/j.1007-9610.2020.01.003

参考文献

[1] Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2017, 3(4):524-548.
[2] Benson AB, D'Angelica MI, Abbott DE, et al. Guidelines insights: hepatobiliary cancers, version 2.2019[J]. J Natl Compr Canc Netw, 2019, 17(4):302-310.
[3] He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs. sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7):953-960.
[4] Song DS, Song MJ, Bae SH, et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. J Gastroenterol, 2015, 50(4):445-454.
[5] Choi JH, Chung WJ, Bae SH, et al. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol, 2018, 82(3):469-478.
[6] Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):60-69.
[7] Kudo M, Matsui O, Izumi N, et al. JSH Consensus-Based Clinical Practice Guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan[J]. Liver Cancer, 2014, 3(3-4):458-468.
[8] Hiramine Y, Uto H, Imamura Y, et al. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study[J]. Exp Ther Med, 2011, 2(3):433-441.
[9] Jeong SW, Jang JY, Lee JE, et al. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma[J]. Asia Pac J Clin Oncol, 2012, 8(2):164-171.
[10] Fukubayashi K, Tanaka M, Izumi K, et al. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method[J]. Cancer Medicine, 2015, 4(8):1214-1223.
[11] Obi S, Sato S, Kawai T. Current status of hepatic arterial infusion chemotherapy[J]. Liver Cancer, 2015, 4(3):188-199.
[12] He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1):83.
[13] Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis[J]. Cancer, 2000, 88(9):1986-1991.
[14] Kawaoka T, Aikata H, Kobayashi T, et al. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma[J]. Hepatol Res, 2018, 48(13):1118-1130.
[15] Ikeda M, Okusaka T, Furuse J, et al. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol, 2013, 72(2):463-470.
[16] Nouso K, Miyahara K, Uchida D, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan[J]. Br J Cancer, 2013, 109(7):1904-1907.
[17] Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leuco-vorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28):3501-3508.
[18] Morito M, Masato S, Yuh S, et al. 5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase Ⅱ study[J]. Hepatol Res, 2012, 42(2):150-165.
[19] Zhuang BW, Li W, Xie XH, et al. Sorafenib versus he-patic arterial infusion chemotherapy for advanced hepato-cellular carcinoma: a systematic review and meta-analysis[J]. Jpn J Clin Oncol, 2019, 49(9):845-855.
[20] Ikeda M, Shimizu S, Sato T, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: rando-mized phase Ⅱ trial[J]. Ann Oncol, 2016, 27(11):2090-2096.
[21] Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(6):424-432.
[22] He MK, Zou RH, Li QJ, et al. Phase Ⅱ Study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis[J]. Cardiovasc Intervent Radiol, 2018, 41(5):734-743.
[23] Chong JU, Choi GH, Han DH, et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2018, 25(11):3308-3315.
[24] Kodama K, Kawaoka T, Aikata H, et al. Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced he-patocellular carcinoma patients with major portal vein tumor thrombosis[J]. Oncology, 2018, 94(4):215-222.
[25] Hamaoka M, Kobayashi T, Kuroda S, et al. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study[J]. Int J Surg, 2017, 44:223-228.
[26] Hatooka M, Kawaoka T, Aikata H, et al. Comparison of outcome of hepatic arterial infusion chemotherapy and sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization[J]. Anticancer Res, 2016, 36(7):3523-3529.
[27] Ikeda M, Mitsunaga S, Shimizu S, et al. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization[J]. J Gastroenterol, 2014, 49(5):932-940.
[28] Moriya K, Namisaki T, Sato S, et al. Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma[J]. J Gastrointest Oncol, 2018, 9(4):741-749.
[29] Shiozawa K, Watanabe M, Ikehara T, et al. Efficacy of sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization[J]. Gan To Kagaku Ryoho, 2015, 42(8):953-956.
[30] Moran A, Ramos LF, Picado O, et al. Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs. resection alone. A systematic review and meta-analysis[J]. J Surg Oncol, 2019, 119(4):455-463.
Options
文章导航

/

〈 〉